Welcome, Guest. Please login or register.
December 06, 2022, 06:55:51 pm

Login with username, password and session length

  • Total Members: 36796
  • Latest: Kaz
  • Total Posts: 766921
  • Total Topics: 65467
  • Online Today: 204
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 2
Guests: 72
Total: 74


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: "New DRug stirs sceintists' hopes of halting AIDS" star ledger3/1/07, page two  (Read 4068 times)

0 Members and 1 Guest are viewing this topic.

Offline motherinneed

  • Member
  • Posts: 76
NJ.com - News - Star-Ledger - New drug stirs scientists' hopes of halting AIDS
An experimental AIDS drug, years in the making by scientists from Johnson & Johnson and Rutgers University, is part of an assortment of startlingly effective new treatments shown to zap resistant strains of HIV. Scientists from J&J's Tibot...
- NJ: Star-Ledger (Article) : Read More

New drug stirs scientists' hopes of halting AIDS
Thursday, March 01, 2007
Star-Ledger Staff
An experimental AIDS drug, years in the making by scientists from Johnson & Johnson and Rutgers University, is part of an assortment of startlingly effective new treatments shown to zap resistant strains of HIV.

Scientists from J&J's Tibotec division reported the results yesterday at the end of a major AIDS conference in Los Angeles. The drug, TMC-278, has long been viewed as the most promising of a family of revolutionary AIDS compounds called "DAPY" (rhymes with "happy') being developed by the New Brunswick drug giant.
"Right now, it looks as if this could be a home run for patients," said Roger Pomerantz, president of J&J's Tibotec Pharma Ltd. in Yardley, Pa., minutes after a presentation before a standing-room-only crowd of 4,000. "I am very jazzed about this. It's going to have a huge impact."

The J&J AIDS presentation followed a equally riveting talk by scientists from Gilead Sciences Inc. in California on their treatment advances, as well as announcements on Tuesday by Merck & Co. of Whitehouse and Pfizer of New York of major strides in AIDS treatment. All of the new drugs attack difficult-to-treat "resistant" strains of the virus and that news has energized the AIDS community.

"It's a brand-new day," said Stephen Smith, a physician-scientist who directs the department of infectious disease at Saint Michael's Medical Center in Newark. "This means that no one in the developed world should be walking around anymore with any detectable levels of virus in their blood. These drugs are just blowing me away."

The announcements made at the 14th annual Conference on Retroviruses and Opportunistic Infections, according to Smith and other experts, are as revolutionary as the breakthroughs of the mid-1990s when scientists developed drug cocktails to stop AIDS.

Merck's drug, MK-0518, blocks an enzyme called integrase that helps the virus replicate. The company plans to seek federal approval before July 1 to use the drug against resistant HIV, the deadly virus that causes AIDS. Gilead also presented promising results from tests on its integrase inhibitor, GS-9137, which is in second-stage testing.

Pfizer's HIV pill, named maraviroc, is the first of a new class of medicines called CCR5 inhibitors that block a chemical doorway used by the virus to infect cells. A chemical cocktail that included maraviroc suppressed the drug in patients who do not respond to older treatments, scientists reported.

Resistant strains, caused when the quick-change artist that is HIV morphs its shape and structure to survive lethal drug attacks, is a huge and growing medical problem. About 10 percent of new HIV patients are infected with a virus resistant to at least one type of AIDS drug, according to a study released earlier this week by the federal Centers for Disease Control and Prevention in Atlanta. And five people in 1,000, according to the study, suffer from a form that evades all three major AIDS therapies currently available.

TMC-278 ("Tibotec medical compound") is a non-nucleoside reverse transcriptase inhibitor. Like other drugs in this category, it jams the machinery of reverse transcriptase, one of the prime proteins responsible for the reproduction of HIV.

CONTINUED   1 | 2  Next


But 278 is a DAPY compound, so it is special, according to its designers. So named because they have diarylpyrimidine at their core, these drugs are made of flexible molecules that find ways to fit into portals on the surface of proteins, like a master key adjusting to many locks.

"This drug sort of bobs and weaves, if you will, and stays in the pocket," said Pomerantz of Tibotec.


In data presented at the conference, Tibotec scientists said the drug was as effective at lowering HIV levels in newly diagnosed patients as Bristol-Myers Squibb's popular Sustiva.

Anton Pozniak, managing director of St. Stephen's AIDS Trust in London, who led the study, said drug combinations that included TMC-278 at three different dose levels lowered the amount of HIV as much as standard doses of Sustiva used in similar combinations.

The drug can be easily combined with others to form a single pill, company officials said, and causes fewer side effects than others on the market. In addition, the drug appears to be non-toxic to pregnant women and their fetuses, which could be an enormous benefit in the developing world where so many of the newly infected patients are women.

Two other Tibotec drugs, also DAPY compounds, are making steady progress, Pomerantz said. TMC-125, which does not combine as well into a single pill but is potent against the virus, has moved through clinical trials and is close to FDA approval. TMC-120 is being studied for its use as a microbicide (an AIDS cream) and has passed initial safety tests, he said.

Research teams at the Center for Advanced Biotechnology and Medicine on Rutgers' Busch campus have studied reverse transcriptase as well as the DAPY compounds for more than a decade. Over the past year, Rutgers researcher Joseph Bauman created a detailed image of TMC-278 through crystallography, technology that reveals the atomic structures of compounds. He then interlocked TMC-278 with reverse transcriptase, an advance expected to lead to new drugs made from DAPY compounds.

"Any time that basic science can lead to new, ideal options for patients with dreadful disease, that's a triumph of enormous magnitude," said Eddy Arnold of Rutgers University, an AIDS expert who supervised Bauman and has long investigated the intricacies of reverse transcriptase.

Kitta MacPherson may be reached at kmacpherson@starledger.com

Previous  | 1 | 2
« Last Edit: March 02, 2007, 11:19:34 am by motherinneed »

Offline Central79

  • Member
  • Posts: 527
Yes - this is Tibotec's new NNRTI. I just hope it's more robust than the others... about time we had a "second generation" of NNRTI drugs.
Diagnosed January 2006
26/1/06 - 860 (22%), VL > 500,000
24/4/06 - 820 (24.6%), VL 158,000
13/7/06 - 840 (22%), VL 268,000
1/11/06 - 680 (21%), VL 93,100
29/1/07 - 1,020 (27.5%), VL 46,500
15/5/07 - 1,140 (22.8%), VL not done.
13/10/07 - 759 (23.2%), VL 170,000
6/11/07 - 630 (25%), VL 19,324
14/1/08 - 650 (21%), VL 16,192
15/4/08 - 590 (21%), VL 40, 832


Terms of Membership for these forums

© 2022 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.